Secretome survey of human plexiform neurofibroma derived schwann cells reveals a secreted form of the RARRES1 protein

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 9380-9399

  Chen, Hui Ling ^a   Seol, Haeri ^a   Brown, Kristy Jean ^a   Gordish Dressman, Heather ^a   Hill, Ashley ^a   Gallo, Vittorio ^a   Packer, Roger ^a   Hathout, Yetrib ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Plexiform neurofibroma; Retinoic acid receptor responder protein1; Schwann cells; Secretome

Indexed keywords

MEMBRANE PROTEIN; PLASMINOGEN; RETINOIC ACID; RETINOIC ACID RECEPTOR RESPONDER PROTEIN 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RARRES1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; COMPLEMENT SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; NERVE CELL CULTURE; NEUROFIBROMA; NUCLEOTIDE SEQUENCE; PEPTIDE MAPPING; PLEXIFORM NEUROFIBROMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOMICS; SCHWANN CELL; TANDEM MASS SPECTROMETRY; DOSE RESPONSE; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEUROFIBROMA, PLEXIFORM; SCHWANN CELLS; TRETINOIN;

EID: 84864356291     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13079380     Document Type: Article

References (45)

1. Goldberg, N.S.; Collins, F.S. The hunt for the neurofibromatosis gene. Arch. Dermatol. 1991, 127, 1705-1707.
2. Korf, B.R. Plexiform neurofibromas. Am. J. Med. Genet. 1999, 89, 31-37.
3. Parrinello, S.; Lloyd, A.C. Neurofibroma development in NF1--insights into tumour initiation. Trends Cell Biol. 2009, 19, 395-403.
4. Lantieri, L.; Meningaud, J.P.; Grimbert, P.; Bellivier, F.; Lefaucheur, J.P.; Ortonne, N.; Benjoar, M.D.; Lang, P.; Wolkenstein, P. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: A 1-year follow-up study. Lancet 2008, 372, 639-645.
5. Needle, M.N.; Cnaan, A.; Dattilo, J.; Chatten, J.; Phillips, P.C.; Shochat, S.; Sutton, L.N.; Vaughan, S.N.; Zackai, E.H.; Zhao, H.; et al. Prognostic signs in the surgical management of plexiform neurofibroma: The Children's Hospital of Philadelphia experience, 1974-1994. J. Pediatr. 1997, 131, 678-682.
6. Serletis, D.; Parkin, P.; Bouffet, E.; Shroff, M.; Drake, J.M.; Rutka, J.T. Massive plexiform neurofibromas in childhood: Natural history and management issues. J. Neurosurg. 2007, 106, S363-S367.
7. Lee, M.J.; Stephenson, D.A. Recent developments in neurofibromatosis type 1. Curr. Opin. Neurol. 2007, 20, 135-141.
8. Bhatheja, K.; Field, J. Schwann cells: Origins and role in axonal maintenance and regeneration. Int. J. Biochem. Cell Biol. 2006, 38, 1995-1999.
9. Serra, E.; Rosenbaum, T.; Winner, U.; Aledo, R.; Ars, E.; Estivill, X.; Lenard, H.G.; Lazaro, C. Schwann cells harbor the somatic NF1 mutation in neurofibromas: Evidence of two different Schwann cell subpopulations. Hum. Mol. Genet. 2000, 9, 3055-3064.
10. Johansson, G.; Mahller, Y.Y.; Collins, M.H.; Kim, M.O.; Nobukuni, T.; Perentesis, J.; Cripe, T.P.; Lane, H.A.; Kozma, S.C.; Thomas, G.; et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol. Cancer Ther. 2008, 7, 1237-1245.
11. Kissil, J.L.; Blakeley, J.O.; Ferner, R.E.; Huson, S.M.; Kalamarides, M.; Mautner, V.F.; McCormick, F.; Morrison, H.; Packer, R.; Ramesh, V.; et al. What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: New frontiers. Am. J. Med. Genet. A 2012, 152A, 269-283.
12. Staser, K.; Yang, F.C.; Clapp, D.W. Plexiform neurofibroma genesis: Questions of Nf1 gene dose and hyperactive mast cells. Curr. Opin. Hematol. 2010, 17, 287-293.
13. Yang, F.C.; Ingram, D.A.; Chen, S.; Zhu, Y.; Yuan, J.; Li, X.; Yang, X.; Knowles, S.; Horn, W.; Li, Y. et al. Nf1-dependent tumors require a microenvironment containing Nf1+/-and c-kit-dependent bone marrow. Cell 2008, 135, 437-448.
14. Perrin, G.Q.; Li, H.; Fishbein, L.; Thomson, S.A.; Hwang, M.S.; Scarborough, M.T.; Yachnis, A.T.; Wallace, M.R.; Mareci, T.H.; Muir, D. An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Lab. Invest. 2007, 87, 1092-1102.
15. Nagpal, S.; Patel, S.; Asano, A.T.; Johnson, A.T.; Duvic, M.; Chandraratna, R.A. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J. Invest. Dermatol. 1996, 106, 269-274.
16. Sahab, Z.J.; Hall, M.D.; Zhang, L.; Cheema, A.K.; Byers, S.W. Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26. J. Cancer 2010, 1, 14-22.
17. Wakoh, T.; Uekawa, N.; Terauchi, K.; Sugimoto, M.; Ishigami, A.; Shimada, J.; Maruyama, M. Implication of p53-dependent cellular senescence related gene, TARSH in tumor suppression. Biochem. Biophys. Res. Commun. 2009, 380, 807-812.
18. Cheng, T.W.; Gong, Q. Secreted TARSH regulates olfactory mitral cell dendritic complexity. Eur. J. Neurosci. 2009, 29, 1083-1095.
19. Hunter, S.; Weiss, S.; Ou, C.Y.; Jaye, D.; Young, A.; Wilcox, J.; Arbiser, J.L.; Monson, D.; Goldblum, J.; Nolen, J.D. et al. Apolipoprotein D is down-regulated during malignant transformation of neurofibromas. Hum. Pathol. 2005, 36, 987-993.
20. West, R.B.; Harvell, J.; Linn, S.C.; Liu, C.L.; Prapong, W.; Hernandez-Boussard, T.; Montgomery, K.; Nielsen, T.O.; Rubin, B.P.; Patel, R. et al. Apo D in soft tissue tumors: A novel marker for dermatofibrosarcoma protuberans. Am. J. Surg. Pathol. 2004, 28, 1063-1069.
21. Abelev, G.I. Production of embryonal serum alpha-globulin by hepatomas: Review of experimental and clinical data. Cancer Res. 1968, 28, 1344-1350.
22. Debruyne, E.N.; Delanghe, J.R. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications. Clin. Chim. Acta 2008, 395, 19-26.
23. Masopust, J.; Kithier, K.; Radl, J.; Koutecky, J.; Kotal, L. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int. J. Cancer 1968, 3, 364-373.
24. McIntire, K.R.; Waldmann, T.A.; Moertel, C.G.; Go, V.L. Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 1975, 35, 991-996.
25. Li, M.S.; Li, P.F.; Yang, F.Y.; He, S.P.; Du, G.G.; Li, G. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res. 2002, 12, 151-156.
26. Rao, J.S. Molecular mechanisms of glioma invasiveness: The role of proteases. Nat. Rev. Cancer 2003, 3, 489-501.
27. Siren, V.; Peltonen, J.; Vaheri, A. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas. Arch. Dermatol. Res. 2006, 297, 421-424.
28. Aviezer, D.; Hecht, D.; Safran, M.; Eisinger, M.; David, G.; Yayon, A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994, 79, 1005-1013.
29. Camaj, P.; Seeliger, H.; Ischenko, I.; Krebs, S.; Blum, H.; de Toni, E.N.; Faktorova, D.; Jauch, K.W.; Bruns, C.J. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol. Chem. 2009, 390, 1293-1302.
30. Xu, Y.; Tan, L.J.; Grachtchouk, V.; Voorhees, J.J.; Fisher, G.J. Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J. Biol. Chem. 2005, 280, 42694-42700.
31. Tarcic, G.; Boguslavsky, S.K.; Wakim, J.; Kiuchi, T.; Liu, A.; Reinitz, F.; Nathanson, D.; Takahashi, T.; Mischel, P.S.; Ng, T. et al. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr. Biol. 2009, 19, 1788-1798.
32. Caccia, D.; Zanetti Domingues, L.; Micciche, F.; de Bortoli, M.; Carniti, C.; Mondellini, P.; Bongarzone, I. Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways. J. Proteome Res. 2011, 10, 4196-4207.
33. Wu, C.C.; Hsu, C.W.; Chen, C.D.; Yu, C.J.; Chang, K.P.; Tai, D.I.; Liu, H.P.; Su, W.H.; Chang, Y.S.; Yu, J.S. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol. Cell Proteomics 2010, 9, 1100-1117.
34. An, E.; Gordish-Dressman, H.; Hathout, Y. Effect of TNF-alpha on human ARPE-19-secreted proteins. Mol. Vis. 2008, 14, 2292-2303.
35. An, E.; Sen, S.; Park, S.K.; Gordish-Dressman, H.; Hathout, Y. Identification of novel substrates for the serine protease HTRA1 in the human RPE secretome. Invest. Ophthalmol. Vis. Sci. 2010, 51, 3379-3386.
36. Formolo, C.A.; Williams, R.; Gordish-Dressman, H.; MacDonald, T.J.; Lee, N.H.; Hathout, Y. Secretome signature of invasive glioblastoma multiforme. J. Proteome Res. 2011, 10, 3149-3159.
37. Norheim, F.; Raastad, T.; Thiede, B.; Rustan, A.C.; Drevon, C.A.; Haugen, F. Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. Am. J. Physiol. Endocrinol. Metab. 2011, 301, E1013-E1021.
38. Roelofsen, H.; Dijkstra, M.; Weening, D.; de Vries, M.P.; Hoek, A.; Vonk, R.J. Comparison of isotope-labeled amino acid incorporation rates (CILAIR) provides a quantitative method to study tissue secretomes. Mol. Cell Proteomics 2009, 8, 316-324.
39. Kishi, K.; Imanishi, N.; Ohara, H.; Ninomiya, R.; Okabe, K.; Hattori, N.; Kubota, Y.; Nakajima, H.; Nakajima, T. Distribution of adipose-derived stem cells in adipose tissues from human cadavers. J. Plast. Reconstr. Aesthetic Surg. 2010, 63, 1717-1722.
40. Jing, C.; El-Ghany, M.A.; Beesley, C.; Foster, C.S.; Rudland, P.S.; Smith, P.; Ke, Y. Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J. Natl. Cancer Inst. 2002, 94, 482-490.
41. Youssef, E.M.; Chen, X.Q.; Higuchi, E.; Kondo, Y.; Garcia-Manero, G.; Lotan, R.; Issa, J.P. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res. 2004, 64, 2411-2417.
42. Kwok, W.K.; Pang, J.C.; Lo, K.W.; Ng, H.K. Role of the RARRES1 gene in nasopharyngeal carcinoma. Cancer Genet. Cytogenet. 2009, 194, 58-64.
43. Wu, C.C.; Shyu, R.Y.; Chou, J.M.; Jao, S.W.; Chao, P.C.; Kang, J.C.; Wu, S.T.; Huang, S.L.; Jiang, S.Y. RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur. J. Cancer 2006, 42, 557-565.
44. Sahab, Z.J.; Hall, M.D.; Me Sung, Y.; Dakshanamurthy, S.; Ji, Y.; Kumar, D.; Byers, S.W. Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the alpha-tubulin tyrosination cycle. Cancer Res. 2011, 71, 1219-1228.
45. Link, A.J.; Eng, J.; Schieltz, D.M.; Carmack, E.; Mize, G.J.; Morris, D.R.; Garvik, B.M.; Yates, J.R., 3rd. Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 1999, 17, 676-682.